Psilocybin Shows Promise as First Effective Treatment for Cocaine Use Disorder

For decades, cocaine use disorder has stubbornly resisted pharmacological intervention. While medications like methadone and buprenorphine transformed treatment for opioid addiction, those struggling with cocaine dependence have faced a stark reality: no FDA-approved medications exist to help them quit. Behavioral therapies alone, while beneficial, leave many trapped in cycles of relapse.

That landscape may be shifting. A randomized clinical trial conducted at the University of Alabama at Birmingham and published May 7, 2026, in JAMA Network Open offers the most rigorous evidence yet that psilocybin—the psychoactive compound found in certain mushrooms—could become the first effective pharmacological treatment for cocaine addiction.

The Study: A Nine-Year Journey

Led by Dr. Peter Hendricks, professor in UAB's Department of Psychiatry and Behavioral Neurobiology, the research team spent nearly a decade developing and testing their protocol. The study randomized 40 adults with cocaine use disorder to receive either a single dose of psilocybin (25 milligrams per 70 kilograms of body weight) or an active placebo. All participants also received cognitive behavioral therapy one month before and after the psychedelic session.

What distinguished this trial was not merely its findings but its participants. Of the 40 individuals enrolled, 33 were Black, and most had annual incomes below $20,000—a demographic historically underrepresented in psychedelic research. This intentional focus on vulnerable, underrepresented populations addresses a critical gap in addiction science, where treatment advances often fail to reach those who need them most.

Results That Defy Placebo

The outcomes, measured 180 days after treatment through follow-back interviews and urinalysis, painted a striking picture. Participants who received psilocybin demonstrated a higher percentage of cocaine-abstinent days compared to those in the placebo group. More dramatically, 30% of the psilocybin group achieved complete abstinence from cocaine at the six-month mark—versus none in the placebo condition.

Those who continued using cocaine after psilocybin treatment also showed benefits. They experienced greater latency to first lapse, meaning they stayed abstinent longer before any return to use. This pattern suggests the intervention may work not merely by suppressing cravings temporarily but by fundamentally altering the relationship between the individual and their substance use.

Dr. Hendricks and his team grounded their hypothesis in earlier research demonstrating psilocybin's anti-addictive properties for smoking cessation and alcohol use disorder. The current findings extend this promise to stimulant addiction, potentially broadening the scope of conditions amenable to psychedelic-assisted therapy.

Safety and the Question of Mechanism

The trial reported transient hypertension as the most common adverse effect—a physiological response that resolved without medical intervention. No serious adverse events were attributed to the psilocybin administration itself, supporting the compound's safety profile when administered in controlled clinical settings.

Yet the study's limitations are as instructive as its successes. The sample size of 40 participants, while sufficient for a pilot trial, limits generalizability. More critically, Dr. Hendricks served as the primary therapist—a dual role that introduces potential bias and prevents true blinding of participants to their treatment condition. The study also lacked measures to isolate psilocybin's specific effects from the intensive psychotherapy that accompanied it.

These caveats do not diminish the findings but rather map the terrain for future research. Larger samples across diverse populations, standardized therapeutic protocols, and mechanistic studies to understand how psilocybin alters addiction circuitry remain essential next steps.

The Broader Context: Psychedelics in Addiction Medicine

The UAB study arrives at a pivotal moment for psychedelic medicine. On April 18, 2026, President Trump signed an executive order directing federal agencies to accelerate research into psilocybin, MDMA, and ibogaine for mental health and addiction treatment. The FDA has since granted priority review vouchers to three psychedelic therapy developers, with potential approvals for treatment-resistant depression expected by late 2026.

For addiction specifically, the implications are profound. Cocaine use disorder affects an estimated 25 million people worldwide, with no pharmacological safety net. The emergence of psilocybin as a candidate treatment offers hope not merely for individual recovery but for addressing a massive unmet medical need.

The timing also intersects with growing interest in GLP-1 medications for addiction. Recent NIH-funded research suggests drugs like semaglutide may suppress cravings across multiple substance use disorders by modulating brain reward circuits. Whether psilocybin and GLP-1 agents might eventually complement each other—or whether they target distinct populations and mechanisms—remains an open question that future comparative studies will need to address.

From Research to Practice

Translating these findings into clinical reality faces significant hurdles. Psilocybin remains a Schedule I controlled substance, requiring specialized licensing and supervised administration settings. The therapy model tested at UAB—involving preparation sessions, a full-day psychedelic experience, and integration follow-up—demands substantial clinician time and training. Insurance coverage for such intensive interventions remains uncertain.

Equity concerns also loom. The UAB trial's focus on underrepresented communities was deliberate and necessary, but as psychedelic therapy commercializes, access could skew toward affluent populations able to pay out-of-pocket. Ensuring that the populations who participated in establishing efficacy—low-income Black Americans in this case—are not excluded from eventual treatment availability represents a critical policy challenge.

Dr. Hendricks emphasizes that his team's work represents a beginning, not an endpoint. "Further research should employ larger samples across diverse populations and advance standardization, replicability and understanding of the therapeutic process," he noted in the study's conclusion.

For the millions currently struggling with cocaine addiction, that research cannot come soon enough. After decades of waiting for pharmacological help, the possibility of an effective treatment—one that works not by substituting one drug for another but by potentially transforming the psychological architecture of addiction—offers a glimpse of a different future.

Whether that future materializes will depend on the scientific rigor of follow-up studies, the wisdom of regulatory frameworks, and the commitment to making effective treatments accessible to all who need them—not merely those who can afford them.